FibroBiologics enters $6.15M ATM offering with H.C. Wainwright

FibroBiologics, Inc.

Up to $6.15M of common stock may be sold via at-the-market offering with H.C. Wainwright.
H.C. Wainwright receives 3.0% commission on gross proceeds plus $100K legal reimbursement.
Net proceeds used for working capital and general corporate purposes.
Shares will be sold under existing S-3 shelf (Reg. No. 333-284663).
Company not obligated to sell any shares; no assurance on price or timing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FibroBiologics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $6,150,000 (effective 2026-05-01).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to $6,150,000
Effective: 2026-05-01

Exact text from the filing

On May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $6,150,000

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-201376

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.